CRISPR and CAS Gene Market to Surpass US$ 3,494.4 Million by 2027 - Coherent Market Insights

Global CRISPR and CAS Gene Market, by Product Type (Vector-based Cas, DNA-free Cas, and Others), by Application (Genome Engineering, Disease Models, Functional Genomics, Knockdown/Activation, and Others), by End User (Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 830.7 million in 2020 and is expected to exhibit a CAGR of 22.8% during the forecast period (2020-2027).

Key players in the market and researchers are focused on the development of advanced pooled libraries to facilitate CRISPR researches. For instance, in June 2019, Cellecta, Inc. launched dual-sgRNA libraries designed for CRISPR activation (CRISPRa) and CRISPR interference/repression (CRISPRi) genetic screens. These libraries helped in increasing the efficiency of activation or repression of the target genes.

Market players entered into research collaboration with a service provider, to develop new technologies, which is expected to drive the growth of the market over the forecast period. For instance, in January 2019, CRISPR Therapeutics, a biopharmaceutical company, entered into research collaboration with ProBioGen, a service and technology provider, to develop novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise.

Global CRISPR and CAS Gene Market - Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus (COVID-19) pandemic is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period.

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 140 million cases and 3.0 million deaths due to coronavirus (COVID-19) were reported up till April 18, 2021 across the globe.

Therefore, increasing number of cases has led the market players to focus on growth strategies such as collaborations and agreements in order to ramp up the production of diagnostic tools and meet the demand for COVID-19 diagnostics in the market. In June 2020, Sherlock Biosciences, Inc. entered into partnership with Integrated DNA Technologies, Inc., in order to manufacture Sherlock CRISPR SARS-CoV-2 kit, on a large scale, for the detection of the novel coronavirus that causes COVID-19.

Browse 35 Market Data Tables and 22 Figures spread through 165 Pages and in-depth TOC on Global CRISPR and CAS Gene Market, by Product Type (Vector-based Cas, DNA-free Cas, and Others), by Application (Genome Engineering, Disease Models, Functional Genomics, Knockdown/Activation, and Others), by End User (Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the CRISPR and CAS gene market, click the link below:

https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

The rising prevalence of blood disorders such as sickle cell diseases among the global population is expected to drive the growth of the CRISPR and CAS gene market. According to Centers for Disease Control and Prevention, as of 2016, around 100,000 people in the U.S. were affected by sickle cell diseases or SCDs. Sickle cell diseases are very common among black or African Americans. Around one in 13 babies belonging to the race are born with sickle cell disease.

Key Takeaways of the CRISPR and CAS Gene Market:

• The global CRISPR and CAS gene market is expected to exhibit a CAGR of 22.8% over the forecast period (2020-2027), owing to growth in potential markets, especially in Europe. While, North America is accounted for the major market share.
• Market players are indulged in signing commercialization agreement with other manufacturers, which is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, in September 2020, ERS Genomics Limited, a biotechnology company which provides broad access to the foundational CRISPR-Cas9 intellectual property, signed the commercialization agreement with Applied StemCell, Inc.
• Some of the major players operating in the global CRISPR and CAS gene market include Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., and Mammoth Biosciences, Inc.